Smith Group Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Smith Group Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,438	Closed	-$210K	–	483
2016 Q2	$210K	Buy	9,438 +3,691	+64%	+$91.8K	0.01%	245
2016 Q1	$120K	Buy	5,747 +1,361	+31%	+$33.6K	﹤0.01%	261
2015 Q4	$133K	Buy	4,386 +839	+24%	+$25.4K	﹤0.01%	270
2015 Q3	$88K	Buy	3,547 +498	+16%	+$14.9K	﹤0.01%	274
2015 Q2	$98K	Buy	3,049 +259	+9%	+$9.89K	﹤0.01%	247
2015 Q1	$100K	Buy	+2,790	New	+$76.5K	﹤0.01%	295

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Smith Group Asset Management's RIGL Position: Q3 2016 in Review

Smith Group Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2016, closing a stake of 9,438 shares — an estimated $210K sold.

Smith Group Asset Management first reported a position in RIGL in Q1 2015 and held it in 6 quarters. The position peaked at $210K in Q2 2016. 121 funds tracked by Wall St. Rank hold RIGL as of Q3 2016.

Smith Group Asset Management reported no remaining Rigel Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Smith Group Asset Management sold 9,438 Rigel Pharmaceuticals shares in Q3 2016, an estimated $210K.
Smith Group Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 6 quarters.
Smith Group Asset Management's Rigel Pharmaceuticals position peaked at $210K in Q2 2016.
121 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2016.

Based on Smith Group Asset Management's 13F filing for Q3 2016, filed 2 Nov 2016.